The largest database of trusted experimental protocols

90 protocols using sorafenib

1

Inhibitor Preparation for Cell and Mouse Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
ISO-1 (ISO; MIF antagonist) was purchased from Abcam (Cambridge, MA, USA). Sorafenib, p-toluenesulfonate salt (Sorafenib; VEGF receptor inhibitor) was purchased from LC Laboratories (Woburn, MA, USA). Inhibitors were added to MA prior to incubation with cells or injection into mice, as indicated.
+ Open protocol
+ Expand
2

Cell Migration Analyzed by Scratch Test

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell migration was analyzed using a scratch test. Cells were seeded in 6-wells plates at a density of 4.5 x 105 per well in medium (1% FCS). Following adhesion, medium was removed and a horizontal ‘scratch’ was made in the cell monolayer using a 200-ul pipette tip. Then again medium (1% FCS) was added. Cells were incubated with sorafenib (0–1 uM) ± canertinib (4 uM), canertinib (0–2 uM) ± crizotinib (3 uM) or ± sorafenib (2 uM, LC laboratories). After 1h, growth factors including EGF, HGF or FGF (100 ng/ml, Life Technologies) were added. Cell migration into the scratched area was observed and imaged after 24h and 48h. Medium was refreshed directly before imaging at the later time point.
+ Open protocol
+ Expand
3

Sorafenib Resistance in Huh7 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
A sorafenib-resistant Huh7 cell line was established by long term exposure to incremental concentrations of sorafenib (LC Laboratories, USA) as reported [38 (link)]. Following six months of culture in 10 cm cell culture dishes, resistant cells were diluted out in 96 well plates and single cell clones were selected and scaled up to be used in further experiments.
+ Open protocol
+ Expand
4

Compound Preparation for Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
TTT-3002 was a generous gift of Hanno Roder from TauTaTis, Inc. (San Diego, CA). CEP-701, AC220, sorafenib and PKC412 were purchased from LC Laboratories. Compounds were dissolved in 100% DMSO and prepared as 10μM stock solutions in RPMI with 0.1% DMSO and stored at -80°C.
+ Open protocol
+ Expand
5

pH-Sensitive Copolymer for Drug Delivery

Check if the same lab product or an alternative is used in the 5 most similar protocols
Methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) copolymer with citraconic amide as a pH-sensitive bond (mPEG-pH-PCL) was purchased from Creative PEGWorks (Chapel Hill, NC, USA). Cremophor EL®, dimethyl sulfoxide (DMSO), thiazolyl blue tetrazolium bromide (MTT), and crystal violet were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). Distilled water (DW), ethanol (EtOH), acetonitrile (ACN), and methanol (MeOH) were purchased from Fisher Scientific (Waltham, MA, USA). PTX, RAPA, and sorafenib were purchased from LC Laboratories® (Woburn, MA, USA). ETP was purchased from Tokyo Chemical Industry Co., Ltd. (Chuo-ku, Tokyo, Japan). Sodium chloride (NaCl), potassium phosphate monobasic (KH2PO4), potassium chloride (KCl), sodium phosphate dibasic anhydrous (Na2HPO4), and 0.1 N hydrochloric acid (HCI) standard solution were purchased from Duksan (Seoul, Korea) and were used for the manufacturing of phosphate-buffered saline (PBS). All other reagents and solvents were analytical grade or high-performance liquid chromatography (HPLC) grade.
+ Open protocol
+ Expand
6

Preparation of Tyrosine Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sunitinib malate was kindly provided by Pfizer Oncology (New York, NY). Sorafenib, pazopanib, erlotinib hydrochloride, lapatinib di-p-toluenesulfonate and everolimus were purchased from LC Laboratories (Woburn, MA). All drugs were prepared as 20 mM stock solutions in DMSO (Sigma-Aldrich), except erlotinib hydrochloride, which was prepared as a 10 mM stock solution in 96% DMSO/4% H2O. All stock solutions were stored at −80 °C.
+ Open protocol
+ Expand
7

Sorafenib and 3-BP Cytotoxic Combination

Check if the same lab product or an alternative is used in the 5 most similar protocols
The agent 3-BP was obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Sorafenib was purchased from LC laboratories (Woburn, MA, USA).
+ Open protocol
+ Expand
8

Sorafenib Sensitivity in HCC Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were seeded into 96‐well plates and treated with different concentrations of sorafenib (catalognumber, S‐8502; LC Laboratories, Shanghai, China). Cell viability was examined by MTT assay. The half inhibitory concentration (IC50) value was determined for each HCC cell line. To evaluate the effect of lncRNA, cell viability was measured 96 hours after transfection using the MTT assay (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions.
+ Open protocol
+ Expand
9

Inhibition of Pim Kinases and FLT3-ITD in AML

Check if the same lab product or an alternative is used in the 5 most similar protocols
AZD1208, an orally bioavailable highly selective inhibitor with single nanomolar potency against all three Pim kinases, Pim-1, Pim-2 and Pim-3 (14 (link)), provided by AstraZeneca, was used at 1 μM based on inhibition of BAD phosphorylation at serine 112 as a pharmacodynamic endpoint (16 (link)) and on phase I clinical trial data (11 ). The FLT3 inhibitors quizartinib and crenolanib (Selleck Chemicals, Houston, TX), sorafenib (LC Laboratories, Woburn, MA) and gilteritinib (Active Biochem, Maplewood, NJ), all clinically active in FLT3-ITD AML, were used at pharmacologically relevant concentrations (17 (link)–20 (link)). The proteasome inhibitor MG132 and the USP9X inhibitor WP1130 were purchased from EMD Millipore, Billerica, MA.
+ Open protocol
+ Expand
10

Synergistic Effects of Sorafenib and Ibrutinib on HCC

Check if the same lab product or an alternative is used in the 5 most similar protocols
HCC cells seeded into 96-well plates (3000 cells/well) were allowed to grow overnight followed by treatment with sorafenib (LC Laboratories, Woburn, MA), ibrutinib (Cayman chemicals, Ann Arbor, MI and Acorn PharmaTech, Redwood City, CA) or combination of both. Cell viability was assessed after 72 hours of drug exposure using CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). Each treatment was done in quadruplicate.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!